{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:48:38Z","timestamp":1792288118699,"version":"4.4.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in growth and survival of BCR-ABL transformed cells. AMPK kinase is a metabolic sensor that exhibits suppressive effects on the mTOR pathway and negatively regulates mTOR activity. We report that AMPK activators, such as metformin and 5-aminoimidazole-4-carboxamide ribonucleotide, suppress activation of the mTOR pathway in BCR-ABL\u2013expressing cells. Treatment with these inhibitors results in potent suppression of chronic myeloid leukemia leukemic precursors and Ph+ acute lymphoblastic leukemia cells, including cells expressing the T315I-BCR-ABL mutation. Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL\u2013expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.<\/jats:p>","DOI":"10.1182\/blood-2011-01-332783","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T20:18:16Z","timestamp":1319228296000},"page":"6399-6402","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Antileukemic effects of AMPK activators on BCR-ABL\u2013expressing cells"],"prefix":"10.1182","volume":"118","author":[{"given":"Eliza","family":"Vakana","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center and Division of Hematology\/Oncology, Northwestern University Medical School and Jesse Brown Veterans Administration Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center and Division of Hematology\/Oncology, Northwestern University Medical School and Jesse Brown Veterans Administration Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Glaser","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center and Division of Hematology\/Oncology, Northwestern University Medical School and Jesse Brown Veterans Administration Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Donato","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center and Division of Hematology\/Oncology, Northwestern University Medical School and Jesse Brown Veterans Administration Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019111807321794200_B1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML.","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111807321794200_B2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807321794200_B3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","article-title":"Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"issue":"18","key":"2019111807321794200_B4","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"2019111807321794200_B5","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2019111807321794200_B6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.onc.1209901","article-title":"A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.","volume":"26","author":"Prabhu","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"2019111807321794200_B7","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2004-10-4003","article-title":"Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.","volume":"106","author":"Parmar","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111807321794200_B8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","article-title":"A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation.","volume":"107","author":"Notari","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111807321794200_B9","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"issue":"13","key":"2019111807321794200_B10","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1074\/jbc.M707934200","article-title":"Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR\/p70 S6 kinase pathway.","volume":"283","author":"Carayol","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111807321794200_B11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor.","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"issue":"28","key":"2019111807321794200_B12","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL\u2013expressing leukemic cells.","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111807321794200_B13","first-page":"E1107","article-title":"AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.","volume":"273","author":"Merrill","year":"1997","journal-title":"Am J Physiol"},{"issue":"5","key":"2019111807321794200_B14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111807321794200_B15","doi-asserted-by":"crossref","first-page":"H457","DOI":"10.1152\/ajpheart.00002.2007","article-title":"Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"11","key":"2019111807321794200_B16","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cbt.10.11.13629","article-title":"AMPK as a therapeutic target in renal cell carcinoma.","volume":"10","author":"Woodard","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2019111807321794200_B17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1074\/jbc.M705227200","article-title":"Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.","volume":"283","author":"Altman","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111807321794200_B18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)01006-4","article-title":"Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase.","volume":"353","author":"Sullivan","year":"1994","journal-title":"FEBS Lett"},{"issue":"5","key":"2019111807321794200_B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival.","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"issue":"4","key":"2019111807321794200_B20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2009.300","article-title":"ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.","volume":"24","author":"Wu","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111807321794200_B21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/bies.10009","article-title":"AMP-activated protein kinase: the energy charge hypothesis revisited.","volume":"23","author":"Hardie","year":"2001","journal-title":"Bioessays"},{"issue":"Pt 23","key":"2019111807321794200_B22","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1242\/jcs.01540","article-title":"The AMP-activated protein kinase pathway: new players upstream and downstream.","volume":"117","author":"Hardie","year":"2004","journal-title":"J Cell Sci"},{"issue":"22","key":"2019111807321794200_B23","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"2019111807321794200_B24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.110.175851","article-title":"Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.","volume":"337","author":"Hsu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2019111807321794200_B25","doi-asserted-by":"crossref","first-page":"e7889","DOI":"10.1371\/journal.pone.0007889","article-title":"Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.","volume":"4","author":"Robert","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"2019111807321794200_B26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab"},{"key":"2019111807321794200_B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-6-46","article-title":"Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.","volume":"6","author":"Sengupta","year":"2007","journal-title":"Mol Cancer"},{"issue":"20","key":"2019111807321794200_B28","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111807321794200_B29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2010.06.052","article-title":"AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival.","volume":"398","author":"Woodard","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2019111807321794200_B30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in cancer therapy: a new perspective for an old antidiabetic drug?","volume":"9","author":"Ben Sahra","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111807321794200_B31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/24\/6399\/1342904\/zh805011006399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/24\/6399\/1342904\/zh805011006399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:39:33Z","timestamp":1574062773000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/24\/6399\/29175\/Antileukemic-effects-of-AMPK-activators-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,8]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2011,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-332783","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,8]]}}}